A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants with Relapsed or Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Disease Sites:

Leukemia, Myelodysplastic Syndrome

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

CBX-250

Principal Investigator(s):

Ball, Somedeb

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

09-05-2025

Trial Type:

Treatment

Protocol ID:

VICCHEMP25017

National Clinical Trial ID:

NCT06994676

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available